Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Eric Schmidt and other AI leaders (Karpathy, Musk, Anthropic executives) have described recursive self-improvement (RSI)—AI ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Deploying deep learning models efficiently on heterogeneous hardware remains challenging. Here, authors present a mixed-precision supernetwork that jointly optimizes model mapping and adaptation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results